LRH-1抗體製備及LRH-1調控CYP11A1之研究

Preparation of LRH-1 Antibody & Regulation of CYP11A1 Gene by LRH-1

潘建廷(Chien-Ting Pan)

指導教授 ： 胡孟君

國立臺灣大學/醫學院/生理學研究所/碩士(2005年)

https://doi.org/10.6342/NTU.2005.10287

摘要

CYP11A1基因的產物為膽固醇側鍵截切酶(cholesterol side-chain cleavage enzyme, P450scc)。 P450scc酵素在類固醇荷爾蒙的合成途徑中，負責催化第一個步驟，也就是將膽固醇轉換成孕烯醇酮 (pregenelone)。CYP11A1普遍存在於腎上腺、性腺等所有類固醇生成組織中。Liver receptor homolog-1 (LRH-1)為 NR5A家族中的一員，為一轉錄因子，其大量存在於某些類固醇生成組織內，例如卵巢，並具有調控類固醇生成基因的能力。
我們首先使用大腸桿菌表現系統大量產生小鼠LRH-1 (mLRH-1)兩個不同片段的胜肽，分別是具有N端1~115胺基酸序列及C端169~560胺基酸序列。經電泳純化後，以此製備LRH-1抗體。在西方墨染法中，以所製備的LRH-1抗體，證實LRH-1存在於黃體的初代培養細胞中。293T細胞株經轉染mLRH-1表現質體後，亦能以此抗體偵測到mLRH-1的表現。我們利用共同轉染的方法研究LRH-1調控CYP11A1基因表現的能力。LRH-1對於1.5 kb長度的CYP11A1啟動子，即具有增進其轉錄的作用。CYP11A1基因上的兩個SF-1結合序列(-40和-1600)，經由點突變後發現，位於-40上的SF-1結合序列，可能是LRH-1在CYP11A1基因啟動子上的主要結合序列。轉染Dax-1後，LRH-1增進CYP11A1基因啟動子的作用，會受到抑制。LRH-1會和轉譯後修飾蛋白SUMO-1產生鍵結，而lysine 289為其主要的結合位置。SUMO-1和LRH-1結合後，會抑制LRH-1的轉錄活性，其抑制效果和Dax-1並無關聯。我們發現LRH-1在轉染細胞中的表現並不穩定，當加入proteasome抑制劑MG-132後，可提升其蛋白含量。

關鍵字

轉錄因子 ； 轉譯後修飾蛋白

並列摘要

CYP11A1 gene encodes P450scc enzyme, which controls the first and rate-limiting step of steroidogenesis by conversion of cholesterol to pregnenolone. CYP11A1 gene is expressed in many steroidogenic tissues like adrenal and gonad. Liver receptor homolog-1 (LRH-1) is a transcription factor and belongs to a member of nuclear receptor NR5A family. LRH-1 is expressed in some steroidogenic tissues such as ovary and may play a role in the regulation of steroidogenic gene.
To study the function of LRH-1, two peptides of mouse LRH-1 were produced in E. coli for the generation of antibody. This antibody was used to detect the presence of LRH-1 in rat primary luteal cells by Western blotting. Transfection of LRH-1 expression vector in 293T cell line also can be detected by Western blotting. To examine the ability of LRH-1 in the regulation of CYP11A1 gene expression, we cotransfected LRH-1 expression vector and human CYP11A1 promoter construct into 293T cell line. LRH-1 can enhance the shortest 1.5 kb CYP11A1 promoter activity. Two functional SF-1 binding sites were located at -40 and -1600 in CYP11A1 promoter. By mutating the SF-1 binding sites, we found that SF-1 binding site located at -40 is the major site of LRH-1 binding to CYP11A1 promoter. Induction of CYP11A1 promoter activity by LRH-1 was inhibited by Dax-1. LRH-1 can be conjugated with post-translation modification protein SUMO-1 and we found that lysine 289 is the major conjugation site of SUMO-1. When LRH-1 was conjugated with SUMO-1 the ability of LRH-1 inducing CYP11A1 promoter activity was inhibited and that was independent of Dax-1 function. We found that LRH-1 may not be stable in the transfected cell.The proteasome inhibitor, MG-132, can increase the amount of LRH-1 protein in transfected cell.

並列關鍵字

LRH-1 ； CYP11A1 ； SUMO-1

參考文獻

1. Agarwal, V. R., S. E. Bulun, M. Leitch, R. Rohrich, and E. R. Simpson. 1996. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81:3843-9.

2. Annicotte, J. S., E. Fayard, G. H. Swift, L. Selander, H. Edlund, T. Tanaka, T. Kodama, K. Schoonjans, and J. Auwerx. 2003. Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol 23:6713-24.

3. Bayer, P., A. Arndt, S. Metzger, R. Mahajan, F. Melchior, R. Jaenicke, and J. Becker. 1998. Structure determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol 280:275-86.

4. Ben-Zimra, M., M. Koler, and J. Orly. 2002. Transcription of cholesterol side-chain cleavage cytochrome P450 in the placenta: activating protein-2 assumes the role of steroidogenic factor-1 by binding to an overlapping promoter element. Mol Endocrinol 16:1864-80.

5. Boerboom, D., N. Pilon, R. Behdjani, D. W. Silversides, and J. Sirois. 2000. Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process. Endocrinology 141:4647-56.